A composition comprises, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby is effective in suppressing fat accumulation and can be used as a food or drink, a medicine, and a feed.

A composition comprises, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby is effective in suppressing fat accumulation and can be used as a food or drink, a medicine, and a feed.

The invention describes products, uses thereof, compositions thereof, and methods to prepare products formed from Maillard reaction products from a sugar donor and/or sweet tea extracts, Stevia extracts, swingle (mogroside) extracts, one or more sweet tea extract components, one or more steviol glycosides, one or more mogrosides, one or more glycosylated sweet tea glycosides, one or more glycosylated steviol glycosides or one or more glycosylated mogrosides and an amine donor/reactant.

The invention describes products, uses thereof, compositions thereof, and methods to prepare products formed from Maillard reaction products from a sugar donor and/or sweet tea extracts, Stevia extracts, swingle (mogroside) extracts, one or more sweet tea extract components, one or more steviol glycosides, one or more mogrosides, one or more glycosylated sweet tea glycosides, one or more glycosylated steviol glycosides or one or more glycosylated mogrosides and an amine donor/reactant.

Provided are compositions and methods for oral delivery to an infant of a composition containing Bifidobacterium. The composition may be pre-loaded into or placed directly onto an artificial nipple or pacifier and may also be applied directly to the skin of a caregiver and/or to one of the gums, teeth or cheek of the infant. The compositions of the invention are provided in soft gel fill, dissolvable or disintegrable tablet or powder or semisolid forms and are stable for at least 24 months when stored at 25° C. and 65% relative humidity.

A composition for treating, ameliorating, or preventing an infection in a mammalian urinary tract is provided. The composition comprises a monosaccharide comprising a D-mannose, an oligosaccharide comprising an isolated human milk oligosaccharide (HMO), a flavonoid comprising an A-type proanthocyanidin, quercetin, a vitamin comprising ascorbic acid, a green tea extract, and optionally a triterpenoid comprising ursolic acid. A method of treating, ameliorating, or preventing an infection in a urinary tract of a mammal is also provided, and comprises administering the composition to the mammal.

A composition for treating, ameliorating, or preventing an infection in a mammalian urinary tract is provided. The composition comprises a monosaccharide comprising a D-mannose, an oligosaccharide comprising an isolated human milk oligosaccharide (HMO), a flavonoid comprising an A-type proanthocyanidin, quercetin, a vitamin comprising ascorbic acid, a green tea extract, and optionally a triterpenoid comprising ursolic acid. A method of treating, ameliorating, or preventing an infection in a urinary tract of a mammal is also provided, and comprises administering the composition to the mammal.

A method for preparing a liquid dietary supplement includes extracting kavalactones from a Kava plant, heating water to approximately 160° Fahrenheit, and mixing kavalactones with sugar in a 1:2 ration creating a Kava/sugar mixture. The method also includes pouring Kava/sugar and heated water into a mixer, mixing, for approximately twenty (20) minutes, and pumping mixed Kava/sugar through a filter bag generating a slurry. Further the method includes adding the slurry to water heated to 55° Fahrenheit and agitating the slurry and the water heated to 55° with a mixer.

A method for preparing a liquid dietary supplement includes extracting kavalactones from a Kava plant, heating water to approximately 160° Fahrenheit, and mixing kavalactones with sugar in a 1:2 ration creating a Kava/sugar mixture. The method also includes pouring Kava/sugar and heated water into a mixer, mixing, for approximately twenty (20) minutes, and pumping mixed Kava/sugar through a filter bag generating a slurry. Further the method includes adding the slurry to water heated to 55° Fahrenheit and agitating the slurry and the water heated to 55° with a mixer.

An agent which can play a comparable or superior role to LS in improvement of intestinal tract function, enhancement of immune function, suppression of production of a putrefactive product, improvement of bowel movement or the like and an agent which can play a role in protection of the intestinal tract from a food emulsifier, a lipid peroxide or the like are provided. An intestinal tract function-improving agent, an immunoenhancing agent, a putrefactive product production-suppressing agent, a bowel movement-improving agent and an intestinal tract protection agent each containing a cyclodextrin as an active ingredient are provided. they can play a comparable or superior role to LS in improvement of intestinal tract function, enhancement of immune function, suppression of production of a putrefactive products, improvement of bowel movement or the like and the agent which can play a role in protection of the intestinal tract from a food emulsifier, a lipid peroxide or the like. Using the agents as an active ingredient, an anti-inflammatory agent, an immunostimulant, a body odor-improving agent, a stool odor-improving agent, a laxative, an intestinal tract protection agent and the like can also be provided.